WASHINGTON: Biden Administration, under pressure to increase the supply of coronavirus vaccine to poor countries, plans to spend billions of dollars to expand production capacity, with the aim of generating at least 1 billion additional doses a year starting in the second half of 2022.
This investment is part of a new plan, announced Wednesday by the White House officials, for the government to partner with industry for the needs of vaccines immediately addresses in the United States and abroad and to prepare for future pandemics.
It came on a recent decision to buy enough new pill Covid-19 Pfizer for around 10 million maintenance courses and spend $ 3 billion on an excessive fast test, which is needed to detect the virus quite early for the drug pfizer to work.
Overall, these steps totaled a broad new effort to control the pandemic when Americans were desperate for normal conditions and kasel crawling with the winter approach.
In other developments that the White House hopes to convince the public, food and drug administration tends to approve the request from Pfizer-Bontech and Moderna to offer booster shots to everyone aged 18 years and over.
President Joe Biden has promised to fight Pandemic Coronavirus by making the United States “vaccine warehouse” for the world.
But national personal interests are also working; During the level of vaccination remains low in other parts of the world, allowing viruses to spread, a dangerous new variant can emerge and plunge the United States into a crisis once more.
Expanding the manufacture of vaccines through public-private alliances not without risk.
Until recently, the federal government had a manufacturing partnership with emergency biocalism, which Baltimore facilities destroyed millions of doses of the Coronavirus vaccine Johnson & Johnson earlier this year.
The Biden government severed his relationship by appearing earlier this month.
Zients Jeff, Coordinator of the Biden Coronavirus response, said the government was looking to move quickly, and wanted responses from the industry within 30 days.
Potential partners appear to be limited; Only two main vaccine makers – Pfizer and Moderna – currently use MRNA technology, even though these companies employ contract manufacturers to do work for them.